Faster Detection Is The Ultimate Game Changer In UTI Treatment

Nobody likes a urinary tract infection (UTI), are among the most common of all infections, affecting people of all ages and resulting in ~250,000,000 million UTIs globally each year. Even though UITs are one of the most common infections, only 20-30% of all urine cultures ordered found to be positive for and infection. According to the CDC, Urinary Tract Infections (UTI) account for approximately 10 percent of office visits by women, and the most common reason for prescribing antibiotics.

Doctors and researchers believe that in an ideal world, every patient suspected of having a UTI would get a urine culture and result prior to any prescription of antibiotics. However, in many cases, this is far from a realistic proposition because cultures can take days to show results, slowing down the process and symptoms become unbearable. Without rapid diagnostics, a clinician’s ability to detect pathogens, diagnose an infection and decide on the most effective treatment can be significantly delayed.
The development of quick, affordable diagnostic tools that would allow a faster urine culture so that a doctor can prescribe the right drug for UTIs would help millions of women around the world.

Enter BacterioScan.

BacterioScan’s 216Dx proprietary and patented laser microbial growth technology platform is built on fast detection and antibiotic susceptibility testing of pathogens. It’s precision instrumentation detects and measures microorganism growth in liquid specimens, determines susceptability to a range of antibiotics and provides clinicians with patient-specific guidance on the fastest and most effective antibiotic treatment.

BacterioScan’s goal is for clinicians to have a baseline answer on the presence of a UTI before antibiotics are prescribed. Faster detection means faster results, and a more judicious and informed use of antibiotics.

BacterioScan has designed, manufactured, and commercialized a fast screening device that will eliminate the 60-70 percent of urine cultures that are negative for UTI. Fast screening will provide clinicians with quick answers within three hours so that needless and potentially harmful antibiotics will not be taken by the patients.

When antibiotics are prescribed inappropriately, bacteria can become resistant to antibiotics, diminishing the ability of providers to effectively treat patients with complex health care needs. Antibiotic stewardship programs can improve patient safety and ensure the continued efficacy of antibiotics.

Answers before antibiotics is now a possibility when those microbiology results are available in hours, instead of days. Rapid, accurate, and informed treatment decisions are possible with BacterioScan’s automated rapid diagnostic microbiology platform. Laboratories like PathAdvantage embrace and implementation of this technology into their lab environment is delivering rapid and timely results to physicians to ensure that their patients are taking the right medicine for the right infection at the right time.

The healthcare community knows that antibiotic stewardship is a growing public health concern. BacterioScan and PathAdvantage have come together to do their part to combat misdiagnosis and misuse with UTI.